Read by QxMD icon Read


Keiji Ohashi, Ken-Ei Sada, Yu Nakai, Shun Matsushima, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Yoshia Miyawaki, Michiko Morishita, Takayuki Katsuyama, Eri Katsuyama, Haruki Watanabe, Noriko Tatebe, Mariko Narazaki, Yoshinori Matsumoto, Katsue Sunahori Watanabe, Tomoko Kawabata, Jun Wada
OBJECTIVE: Although several autoantibodies have been identified for polymyositis/dermatomyositis (PM/DM) diagnosis, the clinical impact of these antibodies is yet to be elucidated. METHODS: Patients with PM/DM at Okayama University Hospital from 2012 to 2016 were historically enrolled, and antibody profiles were analyzed using line immunoassay. Hierarchical cluster analysis was performed based on serological analysis of anti-aminoacyl-tRNA synthetase (ARS) antibodies, including anti-Jo-1, PL-7, PL-12, EJ, OJ, and SS-A/Ro-52 antibodies...
June 22, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
Marcos de Lima, Betul Oran, Richard E Champlin, Esperanza B Papadopoulos, Sergio A Giralt, Bart L Scott, Basem M William, Joel Hetzer, Eric Laille, Becky Hubbell, Barry S Skikne, Charles Craddock
BACKGROUND: Relapse is the main cause of treatment failure after allogeneic stem cell transplant (alloSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Injectable azacitidine can improve posttransplant outcomes but presents challenges with exposure and compliance. Oral CC-486 allows extended dosing to prolong azacitidine activity. We investigated use of CC-486 maintenance therapy post-alloSCT. METHODS: Adults with MDS or AML in morphological complete remission at CC-486 initiation (42-84 days post-alloSCT) were included...
June 19, 2018: Biology of Blood and Marrow Transplantation
David A Jacobsohn, Michael R Loken, Mingwei Fei, Alexia Adams, Lisa Eidenschink Brodersen, Brent R Logan, Kwang Woo Ahn, Bronwen E Shaw, Morris Kletzel, Marie Olszewski, Sana Khan, Soheil Meshinchi, Amy Keating, Andrew Harris, Pierre Teira, Reggie E Duerst, Steven P Margossian, Paul L Martin, Aleksandra Petrovic, Christopher C Dvorak, Eneida R Nemecek, Michael W Boyer, Allen R Chen, Jeffrey H Davis, Shalini Shenoy, Sureyya Savasan, Michelle P Hudspeth, Roberta H Adams, Victor A Lewis, Albert Kheradpour, Kimberly A Kasow, Alfred P Gillio, Ann E Haight, Monica Bhatia, Barbara J Bambach, Hilary L Haines, Troy C Quigg, Robert J Greiner, Julie-An Talano, David C Delgado, Alexandra Cheerva, Madhu Gowda, Sanjay Ahuja, Mehmet Ozkaynak, David Mitchell, Kirk R Schultz, Terry J Fry, David M Loeb, Michael A Pulsipher
We enrolled 150 patients in a prospective multi-center study of children with acute myeloid leukemia undergoing hematopoietic stem cell transplant (HSCT) comparing detection of measurable residual (MRD) disease by a "Difference from Normal" flow cytometry (ΔN) approach with assessment of Wilms tumor 1 (WT-1) gene expression without access to the diagnostic specimen. Prospective analysis of the specimens using this approach showed that 23% of patients being screened for HSCT had detectable residual disease by ΔN (0...
June 19, 2018: Biology of Blood and Marrow Transplantation
In-Sung Song, Yu Jeong Jeong, Seung Hun Jeong, Hyoung Kyu Kim, Nam-Chul Ha, MyungGeun Shin, Kyung Soo Ko, Byoung Doo Rhee, Sungbo Shim, Sung-Wuk Jang, Jin Han
Multiple myeloma (MM) is a neoplastic plasma cell disorder with high disease recurrence rates. Novel therapeutic approaches capable of improving outcomes in patients with MM are urgently required. The AKT signalling plays a critical regulatory role in MM pathophysiology, including survival, proliferation, metabolism, and has emerged as a key therapeutic target. Here, we identified a novel AKT inhibitor, HS1793, and defined its mechanism of action and clinical significance in MM. HS1793 disrupted the interaction between AKT and heat shock protein 90, resulting in protein phosphatase 2A-modulated phosphorylated-AKT (p-AKT) reduction...
June 19, 2018: Cancer Letters
Paul G Richardson, Jacob Laubach, Sara Gandolfi, Thierry Facon, Katja Weisel, Peter O'Gorman
In multiple myeloma (MM), maintenance therapy is a longer and less intensive treatment course than initial therapy that is administered after induction to delay disease progression. Maintenance and continuous therapy have been shown to suppress minimal residual disease and deepen and prolong responses, with the goal of improving progression-free survival and overall survival. Areas covered: In this review, we have summarized current clinical trial data on maintenance and continuous therapy in newly-diagnosed MM and relapsed/refractory MM (RRMM), focusing on lenalidomide and bortezomib...
June 22, 2018: Expert Review of Anticancer Therapy
Wenliang Geng, Susan Kearney, Stephen Nelson
Aplastic anemia (AA) is characterized by multilineage cytopenias and bone marrow hypocellularity. Severe AA can be treated with immunosuppressive therapy (IST) and/or allogeneic hematopoietic stem cell transplantation. The thrombopoietin agonist eltrombopag has been shown to induce hematopoietic recovery and transfusion independence in adults with refractory and relapsed AA. Recently, upfront eltrombopag therapy in patients with AA in combination with IST has shown efficacy. Data for its use without concurrent IST in pediatric patients with AA remain sparse...
June 22, 2018: Pediatric Blood & Cancer
Luigi A Sposato, Yick Lam, Chris Karapetis, Sina Vatandoust, Amitesh Roy, Paul Hakendorf, Andrew Dwyer, Dayan de Fontgalland, Paul Hollington, David Wattchow
AIM: Observation with close follow-up ("watch and wait") is a recognized treatment option in patients who achieve a complete clinical response to long course chemoradiotherapy. This review of a prospective database aims to evaluate the clinical outcomes among patients with a complete clinical response managed with observation. METHODS: A prospective study of 32 patients who achieved a complete clinical response was undertaken. The primary outcomes measured were overall and recurrence-free survival, and rate of organ preservation in patients who deferred immediate surgery...
June 22, 2018: Asia-Pacific Journal of Clinical Oncology
Yang Zhang, Fang Wang, Xue Chen, Yu Zhang, Mingyu Wang, Hong Liu, Panxiang Cao, Xiaoli Ma, Tong Wang, Jianping Zhang, Xian Zhang, Peihua Lu, Hongxing Liu
BACKGROUND: Mutations in the colony-stimulating factor 3 receptor (CSF3R) gene occur frequently in chronic neutrophilic leukemia and are rare in de novo acute leukemia. The objective of this study was to assess the incidence of CSF3R mutations in acute leukemia and their association with other genetic abnormalities. METHODS: Amplicon-targeted, next-generation sequencing of 58 genes was performed retrospectively on 1152 patients (acute myeloid leukemia [AML], n = 587; acute lymphoid leukemia [ALL], n = 565)...
June 22, 2018: Cancer
Nur Izyani Kamaruzman, Snigdha Tiash, Maeirah Ashaie, Ezharul Hoque Chowdhury
Breast cancer, the second leading cause of female deaths worldwide, is usually treated with cytotoxic drugs, accompanied by adverse side-effects, development of chemoresistance and relapse of disease condition. Survival and proliferation of the cancer cells are greatly empowered by over-expression or over-activation of growth factor receptors and anti-apoptotic factors. Identification of these key players that cross-talk to each other, and subsequently, knockdown with their respective siRNAs in a synchronous manner could be a promising approach to precisely treat the cancer...
June 22, 2018: Biomedicines
Ferhat Arslan, Bahadir Ceylan, Ahmet Riza Sahin, Özgür Günal, Bircan Kayaaslan, Kenan Uğurlu, Alpaslan Tanoğlu, Gülsen Iskender, Selma Tosun, Aynur Atilla, Fatma Sargin, Ayse Batirel, Ergenekon Karagöz, Abdullah Sonsuz, Ali Mert
In this study, we aimed to determine the late relapse rate in hepatitis C patients with sustained virological response after interferon-based regimens, and evaluated the predictors of late relapse while comparing the real-life data of our country with that of others. A multicenter retrospective study was performed to investigate the data of patients infected with HCV who obtained sustained virological response after classical or pegylated interferon alpha (PegIFNα) and ribavirin (RBV) for 48 weeks. Sustained virological response was based on negative HCV RNA level by PCR at the end of six months after the therapy...
June 1, 2018: Le Infezioni in Medicina
Cristina Alonso Madrigal, Manuela Dobón Rebollo, Viviana Laredo de la Torre, Luis Palomera Bernal, Francisco Agustín García Gil
INTRODUCTION: infection with the hepatitis C virus (HCV) causes significant morbidity and mortality in patients with hemophilia. Finally, patients are considered for a liver transplantation (LT) due to cirrhosis and/or hepatocellular carcinoma (HCC). MATERIAL AND METHODS: we report the cases of congenital coagulopathy and HCV infection that underwent LT in our institution. There were three patients with hemophilia A and one patient with von Willebrand disease (vWD) type 3...
June 22, 2018: Revista Española de Enfermedades Digestivas
Emma Gliddon, Victoria Cosgrove, Lesley Berk, Sue Lauder, Mohammadreza Mohebbi, David Grimm, Seetal Dodd, Carolyn Coulson, Karishma Raju, Trisha Suppes, Michael Berk
OBJECTIVES: MoodSwings 2.0 is an online self-guided intervention for bipolar disorder that includes educational modules, interactive tools, and discussion forums. The primary aim of the study was to determine if participation in MoodSwings 2.0 would result in decreased symptoms of depression and mania compared to the control condition. Secondary aims were to identify improvements in core depression symptoms, quality of life, medication adherence, functioning, and time to relapse. METHODS: This was a three-arm randomized controlled trial that compared two intervention arms against a peer support control group (forum)...
June 21, 2018: Bipolar Disorders
Stefan G Hofmann, Joshua Curtiss
Contemporary classification systems assume that psychiatric disorders are expressions of latent disease entities. However, some critics point to the comorbidity problem and other issues that question the validity of the latent disease model. An alternative to this traditional view is the complex network approach. This approach assumes that disorders exist as systems of inter-connected elements, without requiring that the elements are expressions of latent disease entities. Depending on the structure of the network, change can occur abruptly once the network reaches a tipping point...
June 21, 2018: European Journal of Clinical Investigation
Raheleh Norouzi, Zohreh Hojati, Moein Dehbashi
Interferon beta (IFNβ) is transiently expressed in response to viral infections and widely used to treat relapsing-remitting multiple sclerosis (MS). We introduced mutations in the IFNβ gene (in the 27th and 101st codons and in the Kozak sequence, and also deletion of 3' and 5' unstable, untranslated region, UTR) with the aim of increasing the expression of IFNβ. Computational analyses of mutant and wild-type RNAs and proteins of IFNβ by RNAfold, ASAView, HOPE and Ramachandran plot, and iStable web servers showed that the mutations could decrease RNA stability, protein solvent accessibility, and protein stability but could not change correct folding...
June 21, 2018: Applied Microbiology and Biotechnology
Sonam Puri, Michael Shafique, Jhanelle E Gray
Surgical resection ± chemotherapy ± radiation or stereotactic body radiation therapy (SBRT) are established treatment modalities for resectable stage non-small cell lung cancer (NSCLC), and concurrent chemotherapy with radiation is the therapy of choice for unresectable locally advanced disease. Despite treatment with curative intent, most patients subsequently relapse and develop distant disease. Treatment with checkpoint inhibitors represents a major advancement in the treatment of metastatic NSCLC. Therapy against programed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) is associated with a significant improvement in overall survival in stage IV disease, and these results have led to a great interest in evaluating these agents in earlier-stage NSCLC...
June 21, 2018: Current Treatment Options in Oncology
Takashi Taida, Makoto Arai, Mai Fujie, Naoki Akizue, Kentaro Ishikawa, Yuki Ohta, Shinsaku Hamanaka, Hideaki Ishigami, Kenichiro Okimoto, Keiko Saito, Daisuke Maruoka, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Naoya Kato
Background: There are known associations between inflammatory bowel disease (IBD) and changes in mucosal paracellular permeability. We recently developed a novel catheter that can measure mucosal admittance (MA). Methods: Patients with ulcerative colitis (UC) in clinical remission underwent real-time MA measurement during colonoscopy between June 2014 and July 2015 and were prospectively followed. MA measures were taken from normal-appearing mucosa using the Tissue Conductance Meter (TCM)...
June 19, 2018: Inflammatory Bowel Diseases
Yalcin Bayram, Abdul Kerim Yapici, Fatih Zor, Mehmet Bozkurt, Selim Kilic, Serdar Ozturk, Ahmed M Afifi
Background: Traumatic nasal deformities have a wide spectrum of presentations, which further complicates their management and preoperative planning. Although many methods and algorithms have been proposed for management of specific posttraumatic nasal deformities such as twisted, deviated, saddle or short nose, these algorithms usually focus on a specific deformity in isolation from the remainder of the nose. Objectives: The aim of this study is to present an algorithm for traumatic nasal deformities and to evaluate the functional and aesthetic outcomes of this new algorithm by a preoperative and postoperative quality-of-life questionnaire...
June 20, 2018: Aesthetic Surgery Journal
Valiollah Mehrzad, Abbas Ahmadifar, Mehdi Mahmoudzadeh
Background: This study aimed to determine the effect of Hyper-Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone (CVAD) in the treatment of acute lymphoblastic leukemia (ALL) patients and remission duration. Materials and Methods: During a cross-sectional study in the Seyed Al-Shohada Hospital in Isfahan, patients with ALL who were admitted and treated from 2011 to 2015 because of the risk of ALL were selected and through the records investigation, demographic information, disease information, treatment, remission duration, current status, and duration of survival were collected in the form of data and are sick after going into remission, including the duration and recurrence remission survival time in treatment were analyzed and consequence, whether the patient is going into remission, remission and relapse and survival time based on the duration of treatment were analyzed...
2018: Advanced Biomedical Research
Egor V Batorov, Marina A Tikhonova, Natalia V Pronkina, Irina V Kryuchkova, Vera V Sergeevicheva, Svetlana A Sizikova, Galina Y Ushakova, Tatiana A Aristova, Dariya S Batorova, Elena V Menyaeva, Andrey V Gilevich, Ekaterina Y Shevela, Alexander A Ostanin, Elena R Chernykh
We investigated dynamics of CD4+ FOXP3+ T cell recovery following the high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM) patients. Circulating CD4+ FOXP3+ T cells of 79 MM patients were evaluated using flow cytometry before HDC with auto-HSCT, at the day of engraftment, and following 6 and 12 months. Percentage of CD4+ FOXP3+ T cells restored rapidly following auto-HSCT, became higher than pre-transplant level at the day of engraftment and then subsequently decreased for a year...
June 5, 2018: Oncotarget
Ali Abouelghar, Reem Hasnah, Ghina Taouk, Mohamad Saad, Manale Karam
Background: Natural killer (NK) cells are lymphocytes of the innate immune system that have potent cytotoxic activity against tumor cells. NK cell recognition and activity towards cancer cells are regulated by an integrated interplay between numerous inhibitory and activating receptors acting in concert to eliminate tumor cells expressing cognate ligands. Despite strong evidence supporting the role of NK cells in breast cancer (BC) control, BC still develops and progresses to form large tumors and metastases...
June 5, 2018: Oncotarget
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"